论文信息 - A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable. - 字舞流文

A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable.

R. Rouzier | F. Guyon | P. Colombo | E. Kalbacher | A. Floquet | P. Follana | F. Joly | P. Cottu | P. Morice | C. Pomel | E. Chéreau | F. Selle | F. Lécuru | E. Lambaudie | R. Fauvet | P. Pautier | V. Fourchotte | Y. Ghazi | A. Lesoin | Sandrine Martin